november AG
november AG english
november AG clusters market potentials (9-Months’ Statement 2002)
Ad-hoc-announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
november AG clusters market potentials (9-Months’ Statement 2002)
Erlangen, 2002-11-11. During the first nine month of the year 2002, november AG
has made important progress in its three core units, identif (solutions for
product security and brand protection), directif (Lab-on-a-Strip, nucleic acid
testing), and responsif (patient specific approaches in immunotherapy): By
starting a large-scale field study together with the pharmaceutical company
Bristol-Myers Squibb GmbH the market launch of the DNA based forgery-proof
product security labels has begun. In the field of molecular diagnosis, a first
integrated prototype will be presented until the end of the year. In
immunotherapy, a feasibility study regarding the GMP production of the highly
purified anti-tumor agent was started which will be finished until the end of
the year 2002. Entry into clinical trials will follow in the first half of next
year.
The Erlangen based biotech company also developed well with regard to revenues
and result: the consolidated revenues of the first nine months amounted to 2.5
million EUR. Adjusted by the revenues of the la fontaine subsidiaries that
became deconsolidated in May, 2001, this results in a revenue growth of 12
percent in comparison with last year’s period. For the entire business year, the
november Board expects a growth rate of 15 percent. Despite a 26 percent rise
in R&D costs to a total of 4.8 million EUR plus the marketing costs that became
effective for the first time in this reporting period the consolidated net
result for the first nine months amounts to -6.5 million EUR and thus remains
almost on last year’s level (-6.4 million EUR). In particular, administration
costs have been reduced by 0.6 million EUR (25 percent) to a total of 1.6
million EUR. Including financial and tax result, the consolidated net result for
the reporting period of -3.9 million EUR was slightly better than
last year’s figure of -4.0 million EUR. The balance sheet total on 2002-9-30
amounted to 30.5 million EUR. With shareholders’ equity amounting to 28.1
million EUR the equity ratio remains unchanged at 92 percent of the balance
sheet total. The undiluted earnings per share (EPS and DVFA/SG) amount to -0.57
EUR and thus are pleasingly lower than last year’s figures (-0.61 EUR).
Contact: Dr. P.N. Schröder, Investor & Public Relations
Tel. +49 9131/750 88-868, Fax -899, schroeder@november.de
end of ad-hoc-announcement (c)DGAP 11.11.2002
——————————————————————————–
WKN: 676290; ISIN: DE0006762909; Index:
Listed: Neuer Markt Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf,
Hamburg, München, Hannover und Stuttgart
110934 Nov 02
Latest News
Latest Reports
Upcoming Events
No Events found
Webcasts
No Webcasts found